NAMS | Ticker Profile - Titan Protect

NAMS

NewAmsterdam Pharma Company N.V.

Healthcare · Biotechnology · NGM

$31.52

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$4.3B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-28.31

Based on estimated future earnings — lower means cheaper

Rev Growth

+2.1%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-29.5%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$50.32

+60% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 14 analysts covering this stock

About NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

https://www.newamsterdampharma.com

Country: Netherlands Employees: 100 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.799

Good returns relative to risk taken

Kelly Fraction

0.0589

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.838

Acceptable balance between returns and drawdown risk

Annual Return

36.9%

Historical annualised return based on price data

Max Drawdown

-44.0%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

345

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.03

Very low correlation to market moves

52W High

$42.21

25% below the year high

52W Low

$16.95

86% above the year low

Avg Volume

1,142,886

Average daily shares traded — higher means easier to buy and sell

Short Ratio

5.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

7.2%

Moderate short interest

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.78

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.00

Conservative use of debt — low financial risk

Current Ratio

9.76

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

9.56

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-1,921.7%

Profit from core operations before interest and tax

Free Cash Flow

$-58,685,248

Negative — the business is spending more than it generates

Revenue (TTM)

$23M

Total revenue over the last 12 months

Net Income

$-212,732,992

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$59.43

Target Median

$50.32

Target Low

$37.49

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go